BioCentury
ARTICLE | Financial News

F-Prime, Atlas lead Akrevia's $30M series A

September 28, 2018 5:56 PM UTC

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched on Sept. 27 with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture.

Akrevia’s Aklusion platform enables biological molecules such as antibodies, cytokines and chemokines to remain inactive until reaching the tumor microenvironment. Akrevia licensed the technology from City of Hope (Duarte, Calif.) and Thomas Jefferson University (Philadelphia, Pa.)...